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New basal cell carcinoma susceptibility loci
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Asgeir Sigurdsson1, Birte Kehr1, Julius Gudmundsson1, Patrick Sulem1, Bardur Sigurgeirsson2,3,
Kristrun R. Benediktsdottir2,3, Kristin Thorisdottir2,3, Rafn Ragnarsson2,3, Victoria Fuentelsaz4,
Cristina Corredera5, Yolanda Gilaberte6, Matilde Grasa7, Dolores Planelles8, Onofre Sanmartin9,10,
Peter Rudnai11, Eugene Gurzau12, Kvetoslava Koppova13, Bjørn A. Nexø14, Anne Tjønneland15, Kim Overvad16,
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In an ongoing screen for DNA sequence variants that confer risk of cutaneous basal cell
carcinoma (BCC), we conduct a genome-wide association study (GWAS) of 24,988,228 SNPs
and small indels detected through whole-genome sequencing of 2,636 Icelanders
and imputed into 4,572 BCC patients and 266,358 controls. Here we show the discovery of
four new BCC susceptibility loci: 2p24 MYCN (rs57244888[C], OR¼0.76, P¼4.7 10 12),
2q33 CASP8-ALS2CR12 (rs13014235[C], OR¼ 1.15, P¼ 1.5 109), 8q21 ZFHX4
(rs28727938[G], OR¼0.70, P¼ 3.5 10 12) and 10p14 GATA3 (rs73635312[A], OR¼0.74,
P¼ 2.4 10 16). Fine mapping reveals that two variants correlated with rs73635312[A]
occur in conserved binding sites for the GATA3 transcription factor. In addition, expression
microarrays and RNA-seq show that rs13014235[C] and a related SNP rs700635[C]
are associated with expression of CASP8 splice variants in which sequences from intron 8 are
retained.
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B
asal cell carcinoma (BCC) is the most common cancer type
in populations of European ancestry and its incidence has
been increasing. Although it rarely metastasizes, it can be
locally invasive and can cause considerable morbidity. Forty to
ﬁfty per cent of affected individuals develop new primary lesions
within ﬁve years. The economic burden of treating and
monitoring BCC is substantial1,2. In common with other forms
of skin cancer, ultraviolet exposure is a major risk factor3.
Genetics plays a substantial role in BCC. Rare, high-penetrance
inherited mutations in the Hedgehog pathway genes PTCH1,
PTCH2 and SUFU cause Gorlin Syndrome (also called basal cell
nevus syndrome)1,4,5. Somatic mutations in Hedgehog pathway
genes, in addition to TP53, are commonly observed in BCCs1,6.
Genome-wide association and candidate gene studies have
yielded a substantial number of low-to-moderate penetrance
sequence variants that predispose to BCC. Some of the genes
implicated, such as MC1R, ASIP, TYR, SLC45A2, OCA2 and IRF4
also affect pigmentation in Europeans7–13. Their effects on BCC
risk are thought to be mediated at least in part by their inﬂuence
on responses to ultraviolet exposure. Other genes implicated
in BCC predisposition include PADI6/RCC2, RHOU, TERT,
KRT5, CDKN2A/B, KLF14, TP53, TGM3 and RGS22, which
have no obvious relation to ultraviolet-sensitive pigmentation
traits10,14–17.
The Icelandic Cancer Registry has recorded histopathologically
conﬁrmed diagnoses of BCC since 1981, making studies using
population-based case ascertainment possible18. We are
conducting a search for BCC susceptibility loci based on
variants discovered through whole-genome sequencing in the
Icelandic population15. We use long-range phasing and
imputation to determine the genotypes of these variants for
single-nucleotide polymorphism (SNP) microarray chip-typed
individuals and their relatives15,19,20. We now report that we have
sequenced the whole genomes of 2,636 Icelanders to a median
depth of 20 . Genotypes of the variants detected by sequencing
were imputed into 4,572 individuals with BCC (cases) and
266,358 controls using an algorithm that has been improved since
our previous study16,21. Association analysis and replication
genotyping in 1,475 cases and 4,733 control samples from non-
Icelandic populations revealed evidence for four new BCC
susceptibility loci.
Results
Loci associated with BCC. Imputation of genotypes for the
variants identiﬁed by whole-genome sequencing allowed us to
perform 24,988,228 tests of association; 19,543,184 tests for SNPs
and 5,445,044 tests for small indels (o60 bp), testing only alleles
that could be imputed with an information value above 0.8.
Association testing was performed using logistic regression,
treating disease status as the response and genotype counts as
covariates. A Q–Q plot is shown in Supplementary Fig. 1. In
addition to reconﬁrming known BCC susceptibility loci, we
identiﬁed four new loci that displayed substantial association
signals (Supplementary Fig. 2).
We observed BCC association signals at 2p24 from a group of
variants with minor allele frequencies around 10.2%. The
strongest signal came from rs57244888[C], with odds ratio
(OR)¼ 0.77, P¼ 1.4 10 8 (Fig. 1a, Table 1). The peak is in the
intergenic region between MYCN and FAM49A and is separated
from both genes by regions of moderate recombination rates
(Fig. 1a). We generated a single-track Centaurus assay for
rs57244888 and genotyped it in replication samples from Spain,
Denmark and eastern Europe. The association replicated
signiﬁcantly in the non-Icelandic samples (OR¼ 0.74, P¼ 6.9
 10 5) and there was no evidence of heterogeneity between the
sample sets (Table 1). Combining the Icelandic and non-Icelandic
data provided strong overall evidence of an association
(OR¼ 0.76, P¼ 4.7 10 12).
At 2q33, there were signals from a group of variants with
population minor allele frequencies of about 46%, represented by
rs13014235[C] (OR¼ 1.15, P¼ 1.6 10 7, Fig. 1b). Signiﬁcant
replication was obtained in non-Icelandic sample sets (OR¼ 1.15,
P¼ 0.0027) and combining all data sets yielded an OR¼ 1.15,
P¼ 1.5 10 9 (Table 1). rs13014235 is a p.Val34Leu missense
variant in ALS2CR12 (amyotrophic lateral sclerosis 2 chromoso-
mal region, candidate gene 12). The ALS2CR12 gene product is a
structural component of the sperm ﬂagellum22. Considered
together with SIFT and PolyPhen predictions that the
p.Val43Leu change is unlikely to have a functional
consequence, ALS2CR12 seems a weak candidate for a BCC
susceptibility gene.
Many variants are correlated with rs13014235 and they occur
in a region of low recombination rate encompassing several genes
(Fig. 1b). Two attractive candidate genes within the linkage
disequilibrium block are CASP10 and CASP8. These genes encode
initiator caspases of the extrinsic pathways of apoptosis,
controlled by death receptors from the tumour necrosis factor
receptor superfamily23. To highlight this, we designated the locus
2q33 CASP8-ALS2CR12.
We observed a cluster of signals at 8q21 from variant alleles
with protective effects and frequencies around 6.2%, typiﬁed by
rs28727938 [G] (OR¼ 0.70, P¼ 2.1 10 9, Table 1, Fig. 1c).
The signal peak is about 100 kb proximal to the zinc ﬁnger
homeobox 4 (ZFHX4) gene and close to a related antisense non-
coding RNA ZFHX4-AS1. Genotyping of non-Icelandic samples
showed signiﬁcant replication (OR¼ 0.69, P¼ 4.0 10 4) and a
combined Icelandic and non-Icelandic result of OR¼ 0.70,
P¼ 3.5 10 12 (Table 1).
In a peak at 10p14, the strongest signal originated from
rs73635312 with the minor [A] allele showing a protective effect
(OR¼ 0.73, P¼ 2.3 10 13) and a population frequency of
12.6% (Fig. 1d, Table 1). The peak occurs in the region of the
lincRNAs RP11-428L9.1 and RP11-428L9.2. The closest RefSeq
gene to the peak is GATA3, although it is over 800 kb distal
(Fig. 1d). The association was conﬁrmed outside Iceland
(OR¼ 0.76, P¼ 2.1 10 4). Combining the Icelandic and non-
Icelandic data provided strong evidence of an association
(OR¼ 0.74, P¼ 2.4 10 16, Table 1).
To determine whether any independent signals exist at the loci,
we carried out an association analysis of all variants in each
region ±500 kb surrounding each signal peak, conditioned on
the effect of the top SNP. At 10p14 GATA3, we identiﬁed
rs71483706 (Fig. 1d), whose minor allele conferred increased risk
of BCC and had a frequency of about 32% (OR¼ 1.17, P¼ 2.8
 10 8). In Iceland, rs71483706 retained a signiﬁcant signal
after adjustment for rs73635312 (Padj¼ 4.2 10 6,
ORadj¼ 1.14). However, the association could not be replicated
in the non-Icelandic population samples (P¼ 0.31, OR¼ 1.06).
There was no evidence of secondary signals at any of the other
three loci.
Age at diagnosis. Sporadic BCC is predominantly a cancer of old
age, with the majority of cases occurring in patients over the age
of 60. However, in Gorlin syndrome, BCCs typically begin to
appear in the early teens24. Accordingly, we investigated whether
the variants we detected here and in earlier genome-wide
association studies were associated with an earlier age at
diagnosis of BCC (Supplementary Table 1). None of the four
new variants reported here showed a signiﬁcant association with
age at diagnosis. The BCC variants reported previously had
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modest or no signiﬁcant effects on age at diagnosis, though for
the majority of variants the b estimates were negative. Therefore,
it appears that, unlike the high-penetrance variants associated
with Gorlin syndrome, common BCC predisposing variants have
little impact on age at diagnosis.
Fine mapping of variants to potentially functional sites.
Because whole-genome sequencing was used for the detection
and association testing of variants, we have a reasonably complete
picture of the SNP and small indel variants present in Iceland
down to a frequency of about 0.1%. At each locus, we evaluated
every variant’s candidature for pathogenic effect using two
main criteria: ﬁrst, we searched for variants that are correlated
with the index SNP and whose association with BCC was sta-
tistically indistinguishable from the index SNP. Second, we
looked for co-localization of these variants with biologically
relevant landmarks (see Methods). The results are presented in
Supplementary Data 1.
For the 2p24MYCN locus, one variant besides the top SNP was
highlighted by this process. This SNP, rs73217623, is highly
correlated with the top SNP rs57244888 (r2¼ 1.0, Padj¼ 0.82). It
is located in a DNaseI hypersensitivity site found in 54 cell types
including normal human keratinocytes and in binding sites for
seven transcription factors including CTCF in keratinocytes
(Supplementary Data 1).
For the 2q33 CASP8-ALS2CR12 locus, 195 variants were
indistinguishable from the index SNP rs13014235 with respect to
BCC risk, of which 32 had biologically relevant annotations. Of
note, rs2349075 is highly correlated with rs13014235 (r2¼ 0.99,
Padj¼ 0.75) and is located near an enhancer, which is active in
keratinocytes, amongst other cell types. Keratinocytes and 75
other cell types show evidence of DNaseI hypersensitivity
at this location and DNaseI hypersensitivity is correlated with
expression of CASP8. Ten transcription factors are known to bind
at the site including members of the jun/fos family. The
rs2349075 variant is predicted to alter an AP-1-binding site
(Supplementary Data 1).
At the 8q21 ZFHX4 locus, two alleles of a multi-allelic indel
that could not be distinguished from the top SNP rs28727938 had
regulatory region annotations. However, neither they nor
rs28727938 itself provided compelling evidence of a relevant
function in keratinocytes (Supplementary Data 1).
For the 10p14 GATA3 locus, we noticed that two correlated
variants, SNP rs17413266 and indel rs144203968 (both having
r2¼ 0.90 versus rs73635312), occur in phylogenetically conserved
regions which bind the GATA3 transcription factor. The SNP
rs17413266 also has a Combined Annotation-Dependent
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Figure 1 | New BCC association signals. Loci are (a) 2p24 MYCN, (b) 2q33 CASP8-ALS2CR12, (c) 8q21 ZFHX4 and (d) 10p14 GATA3 loci in the Icelandic
sample. Data are based on association signals (expressed as  log10(P) derived by logistic regression) for variants identiﬁed by whole-genome sequencing
and imputation. The index SNP at each locus is labelled. Other variants are plotted in colours according to their r2 values relative to the index SNP as
indicated in the legend (a). Recombination rates, in cM/Mb and based on Icelandic data, are plotted as red lines. The lower panel sections shows the
locations of RefSeq genes and the chromosomal position (hg18 Build 36). The regions shown are±500 kb from the index SNP except for 10p14 GATA3,
where the region is extended to  1Mb to show the location of the GATA3 gene.
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Depletion Scaled C-score of 20.3, which is in the 98.8th percentile
for an intergenic variant25 (Supplementary Data 1).
Association with expression of CASP8 isoforms. We deter-
mined whether any of the BCC risk variants were associated with
local differences in gene expression (cis-expression quantitative
trait loci (eQTL)) by cross-referencing genotypes to RNA
expression microarray data that we had derived previously from
1,001 blood and 673 adipose tissue samples26. No signiﬁcant
associations were seen for 2p24 MYCN, 8q21 ZFHX4 or 10p14
GATA3. At 2q33, CASP8 generates numerous splice variants
(Fig. 2a). One probe on the microarrays, designated NM_033355,
is in the 30 UTR and captures all major CASP8 isoform transcripts
(Fig. 2c). A second probe, designated NM_033358, is unique to a
small exon located between exons 8 and 9 of the major transcripts
(exon numbering is based on NM_001228). The NM_033358
transcript encodes caspase-8 isoform E, which contains the death
effector domains (DED) but lacks the catalytic domains of
caspase-8 (Fig. 2b). A transcript with an extended exon 8, called
exon 8L (NR_111983) has the capacity to encode a similar DED-
only isoform because the 8L extension contains an in-frame stop
codon. However, splicing of exon 8L to downstream exons may
target the transcript for nonsense-mediated decay27–30. Evidence
for the existence in vivo of DED-only caspase-8 isoforms and
their potential inhibitory effects on apoptosis has been
controversial28,29,31–34.
We found that the BCC risk allele rs13014235[C] is associated
with a signiﬁcant increase in abundance of transcripts containing
the NM_033358 probe sequence in both blood (P¼ 1.9 10 39)
and adipose tissue (P¼ 3.1 10 19). This is accompanied in
adipose by a modest reduction in abundance of the major CASP8
transcripts as detected by probe NM_033355 (Supplementary
Fig. 3). In fact, the expression of the isoform E transcript variant
NM_033358 correlated negatively with expression of the major
CASP8 transcript variants regardless of genotype (P¼ 2.1 10 18,
Supplementary Fig. 4). A search of the surrounding genomic
region identiﬁed rs700635[C], which is a member of the class of
variants that could not be distinguished from rs13014235 with
respect to BCC risk and which exhibited the strongest association
with expression of the isoform E variant NM_033358 (b¼ 0.0698,
P¼ 1.2 10 119 in blood RNA, Fig. 3). It also associated with a
modest decrease in expression of the major CASP8 transcripts and
had a similar pattern in adipose tissue.
Given the biological importance of CASP8, we initiated a more
detailed investigation of its expression. We generated blood RNA-
seq data from an independent set of 261 genotyped individuals.
For rs700635[C], we conﬁrmed that RNA abundance in the
Table 1 | Association of SNPs at four loci with basal cell carcinoma.
SNP Allele Chr Position* Locus Sample set Number of
casesw
Number of
controlsz
Frequency
in controls
OR 95%CI Pvaluey Phet
value||
rs57244888 C 2 16,325,626 2p24 MYCN Iceland 4,572 266,358 0.102 0.77 (0.70, 0.84) 1.4 10 8
Spain Zaragoza 316 1,912 0.128 0.76 (0.58, 1.01) 0.059
Spain Valencia 334 1,989 0.112 0.73 (0.55, 0.97) 0.031
Eastern Europe 521 528 0.126 0.71 (0.54, 0.94) 0.017
Denmark 303 309 0.094 0.74 (0.49, 1.11) 0.15
Combined
Non-Icelandic
1,474 4,738 0.74 (0.63, 0.86) 6.9 10 5 0.99
All Combined 6,046 271,096 0.76 (0.70, 0.82) 4.7 10 12 0.98
rs13014235 C 2 201,923,737 2q33 CASP8-
ALS2CR12
Iceland 4,572 266,358 0.456 1.15 (1.09, 1.21) 1.6 10 7
Spain Zaragoza 312 1,883 0.396 1.16 (0.97, 1.38) 0.094
Spain Valencia 334 1,945 0.399 1.14 (0.96, 1.35) 0.12
Eastern Europe 525 526 0.427 1.14 (0.95, 1.36) 0.15
Denmark 297 303 0.386 1.18 (0.93, 1.50) 0.18
Combined
Non-Icelandic
1,468 4,657 1.15 (1.05, 1.26) 0.0027 1.00
All Combined 6,040 271,015 1.15 (1.10, 1.20) 1.5 109 1.00
rs28727938 G 8 77,641,094 8q21 ZFHX4 Iceland 4,572 266,358 0.062 0.70 (0.62, 0.79) 2.1 109
Spain Zaragoza 313 1,910 0.059 0.66 (0.43, 1.00) 0.050
Spain Valencia 331 1,988 0.065 0.65 (0.44, 0.97) 0.037
Eastern Europe 525 526 0.061 0.72 (0.48, 1.09) 0.12
Denmark 302 309 0.081 0.72 (0.46, 1.12) 0.15
Combined
Non-Icelandic
1,471 4,733 0.69 (0.56, 0.85) 4.0 104 0.98
All Combined 6,043 271,091 0.70 (0.63, 0.77) 3.5 10 12 0.99
rs73635312 A 10 8,976,004 10p14 GATA3 Iceland 4,572 266,358 0.126 0.73 (0.68, 0.80) 2.3x10 13
Spain Zaragoza 313 1,904 0.120 0.81 (0.61, 1.07) 0.14
Spain Valencia 330 1,993 0.114 0.65 (0.48, 0.88) 0.0045
Eastern Europe 526 528 0.153 0.72 (0.56, 0.93) 0.013
Denmark 306 306 0.142 0.93 (0.67, 1.29) 0.68
Combined
Non-Icelandic
1,475 4,731 0.76 (0.66, 0.88) 2.1 104 0.41
All Combined 6,047 271,089 0.74 (0.69, 0.80) 2.4 10 16 0.54
Chr, chromosome; CI, conﬁdence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
*NCBI hg18 Build 36.
wFor Iceland, this is the total number of cases used for association testing, including 2,980 chip genotyped and 1,592 related individuals.
zFor Iceland, this is the total number of controls used, including 87,820 chip genotyped and 178,538 related individuals.
yAssociation testing was done using logistic regression.
||Likelihood ratio test for heterogeneity.
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Figure 2 | CASP8-coding exons, protein domains and locations of probes. (a) Coding exons of the major transcript variants. The positions of exon 8 and
exon 8L are indicated. The transcript variant containing exon 8L is designated ‘NR_’ because the exon 8L sequence contains a stop codon that may render
this RNA species susceptible to nonsense-mediated decay. (b) Procaspase-8 protein domains corresponding to exons, from pfam: IPR001875-DED are the
DED; IPR011600-Pept_C14_cat corresponds to the peptidase catalytic domains. (c) Location of the probe sequences used on the expression microarrays.
The height of the bars corresponds to the relative levels of expression in blood. (d) Location of primer-amplicons used in RT–PCR.
2.0
1.5
1.0
0.5
Ex
pr
es
sio
n 
of
 C
AS
P8
 (N
M_
03
33
58
)
Ex
pr
es
sio
n 
of
 C
AS
P8
 (N
M_
03
33
55
)
Ex
pr
es
sio
n 
of
 C
AS
P8
 (N
M_
03
33
55
)
Ex
pr
es
sio
n 
of
 C
AS
P8
 (N
M_
03
33
58
)
Blood
1.6
1.4
1.2
1.0
0.8
0.6
AA AC CC
AA AC CC
rs700635rs700635
rs700635rs700635
AA AC CC
AA AC CC
1.4
1.2
1.0
0.8
1.4
1.2
1.0
0.8
Adipose
Figure 3 | RNA expression microarray data for CASP8 transcript variants, stratiﬁed by genotype of BCC risk variant rs700635. RNA from blood and
adipose tissue was hybridized to Agilent expression microarrays containing probes for the major CASP8 transcript variants (NM_033355) and the variant
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percentiles (vertical lines). Individual points for each sample are also plotted. (a) Expression of the isoform E transcript variant NM_033358 in blood. eQTL
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NM_033358 probe region is increased in risk allele carriers.
However, RNA-seq revealed that the entire intron 8 sequence
between exon 8L and the probe region is preferentially retained in
carriers (Fig. 4a,b). This coincides with the reduced expression of
the major exons of the CASP8 gene in association with
rs700635[C] (b¼  0.65 P¼ 1.7 10 12, Supplementary
Table 2). Reverse transcription–PCR (RT–PCR) of 76 blood
RNA samples (using probes as shown in Fig. 2d) reconﬁrmed
these ﬁndings (Supplementary Fig. 5).
Retention of intron 8 appears to result from failures to
recognize splice donors at the 30 ends of exon 8 and exon 8L, with
the exon 8L donor being ignored preferentially in rs700635[C]
carriers (P¼ 6.2 10 22, Supplementary Fig. 6). Some intron 8
reads had paired ends spliced from upstream exons, which helped
to establish the sense strand polarity of the retained intron
transcripts. We also saw reads indicating that exon 8 (but not
exon 8L) can splice to the NM_033358 probe region. However,
the efﬁciency of this splice did not vary by genotype (P¼ 0.89,
Supplementary Fig. 6). Of the 195 variants that were indis-
tinguishable from the index SNP with respect to BCC risk, none
occurred at the exon 8 or 8L splice donor sites or the exon 9 splice
acceptor. Limited data are available from intron 8 beyond the
probe region, as there is very restricted read coverage 30 to the
NM_033358 probe in both RNA and DNA sequences. Never-
theless, we did detect RNA-seq read pairs crossing the intron 8–
exon 9 boundary, suggesting that the entirety of intron 8 fails to
splice out in association with rs700635[C].
To investigate whether similar phenomena occur at CASP8 in
epidermis, we obtained RNA-seq and genotype data from the
GTEx project35 and analysed them using the same methods as
described above (Supplementary Fig. 7). In sun-exposed skin, we
again found that intron 8 including the NM_033358 probe
sequence is expressed preferentially in association with the
rs700635[C] BCC risk allele (b¼ 1.17, P¼ 1.8 10 24 for intron
8, Supplementary Table 2). The major CASP8 isoform variants
were also expressed at reduced levels in BCC risk allele carriers in
sun-exposed skin (b¼  0.64, P¼ 7.2 10 9), in agreement
with our ﬁndings in blood and adipose tissue. We did notice that
preferential expression from rs700635[C] extended to sequences
in exon 8 and intron 7, which was not seen by us in blood and
remains unexplained (Supplementary Fig. 7). A search of the
GTEx sun-exposed skin RNA-seq data for eQTLs related to the
lead SNPs at 2q24 MYCN, 8q21 ZFHX4 and 10p14 GATA3
yielded no signiﬁcant associations.
Risk variants for other cancers at CASP8. CASP8 has been
implicated in several cancer types both through germline variants
and somatic mutations. The p.Asp302His germline variant
rs1045485[C] has been associated with protection from breast
cancer36,37. We conﬁrmed this association to nominal signiﬁcance
in the Icelandic population (OR¼ 0.93, P¼ 0.031). However, we
saw no effect of the allele on BCC risk (OR¼ 1.04, P¼ 0.31, 95%
conﬁdence interval (CI)¼ 0.97–1.11). CASP8 was also suggested as
the likely candidate gene underlying the effect of a melanoma
susceptibility variant in ALS2CR12 (rs13016963) (ref. 38). In our
data, we could not see evidence of this melanoma association
(OR¼ 1.04, P¼ 0.40, 95% CI¼ 0.96–1.12). There was a nominal
association of rs13016963 with BCC (OR¼ 1.08, P¼ 0.0036) but it
was fully accounted for by rs13014235, the index BCC SNP at the
locus (Padj¼ 0.79). A common chronic lymphocytic leukaemia risk
variant39 did not show a BCC association (rs3769825, OR¼ 1.03,
P¼ 0.35, 95% CI¼ 0.97–1.08 ), nor did the so-called  652 6N del
CASP8 promoter deletion (rs3834129) that has been
controversially implicated in susceptibility to a variety of
cancers40,41 (OR¼ 0.95, P¼ 0.069, 95% CI¼ 0.91–1.00).
Moreover, we have not as yet detected a signiﬁcant association
between the BCC index SNP rs13014235 and any other type of
cancer documented by the Icelandic Cancer Registry. Recently, Lin
et al.42 reported an association between rs1830298 in ALS2CR12
and breast cancer. That variant is highly correlated with the
strongest CASP8 eQTL variant we report (rs700635, r2¼ 1.0). We
conﬁrmed the association with breast cancer for rs700635
(OR¼ 1.08, P¼ 0.0053), but did not see a signiﬁcant association
with rs13014235 (OR¼ 1.03, P¼ 0.27). This suggests a complex
pattern of cancer risk associations at the locus, reminiscent of the
TERT-CPTLM1L locus previously identiﬁed in our BCC genome-
wide association study17.
Discussion
We report here on the discovery of four new susceptibility loci for
BCC. At the 2q24 locus, MYCN is a known oncogene with
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Figure 4 | Carriers of the rs700635[C] BCC risk allele show preferential retention of CASP8 intron 8. RNA-seq data was obtained from blood from
genotyped donors. These were n¼ 24 rs700635[C/C] homozygotes (shown in red), n¼ 117 rs700635[C/A] heterozygotes (shown in green) and n¼ 114
rs700635[A/A] homozygotes (shown in blue). The x axis is the genomic position in Mb (hg18/Build36). The y axis is, for each genotypic group, the
median count of normalized reads (normalized for each individual to the total number of aligned reads). The structure of the RefSeq transcript variants is
shown beneath the graphs. (a) The genomic region covering the coding exons of CASP8. (b) Zoom showing the exon 8, exon 8L region extending through
intron 8 to the minor exon targeted by the NM_033358 probe. (c) Zoom showing the splice junction between exon 8L and intron 8.
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involvement in neuroblastoma and medulloblastoma43,44;
however, it has not been implicated previously in BCC.
Similarly, there are no reports of an involvement of ZFHX4 in
cancer predisposition. CASP8 and GATA3, on the other hand, do
have known associations with both oncogenesis and epidermal
development.
Following death receptor ligation, procaspase-8 is recruited to
the cytoplasmic death-inducing signalling complex (DISC)
through interactions involving its DED. Recruitment of procas-
pase-8 to the DISC leads to its dimerization and activation
through induced proximity. Full activation of caspase-8 results
from cleavage of the catalytic domains from the DED and release
of the dimerized catalytic domains from the DISC23. Our ﬁndings
indicate that in BCC risk allele carriers there is a preferential
retention of the intron following exons 8 and 8L. RNA species
with this structure have the capacity to encode caspase-8
isoforms, which contain the DED but lack the catalytic
domains. Conceptually, an isoform with this structure has the
potential to inhibit caspase-8 signalling by interfering with the
binding of full-length procaspase-8 to the DISC. Indeed some
(but not all) investigators have observed anti-apoptotic effects
resulting from the expression of DED-only caspase-8
isoforms28,33,34. If the RNA species run through to exon 9,
splicing of exon 9 to exon 10 could, however, render the
transcripts susceptible to nonsense-mediated decay. Coincident
with the intron retention is a reduction in overall expression of
the major transcript variants of CASP8. Combined, these factors
could suppress caspase-8 signalling in risk allele carriers.
One predictable outcome of reduced caspase-8 signalling might
be a failure of incipient tumour cells to undergo apoptosis.
During normal epidermal development there does not, however,
seem to be an involvement of activated pro-apoptotic caspases45.
Conditional knockout mice where CASP8 is speciﬁcally disabled
in epidermal keratinocytes develop a lethal neonatal skin
inﬂammation and hyperplasia46,47. Double knockout of CASP8
and the necroptosis-associated kinase RIPK3 rescues mice from
neonatal lethality, skin inﬂammation and hyperplasia23,48. This
suggests that CASP8 normally functions to suppress necroptosis
and consequent inﬂammation in epidermis. It is therefore
possible that an inhibition of caspase-8 signalling in BCC risk
allele carriers could act to promote necrosis and inﬂammation,
thereby generating a tumour-promoting environment within the
epidermis.
We caution that while the effect of rs700635 on the expression
of CASP8 is robustly proven and the SNP is associated with risk
of BCC (OR¼ 1.15, P¼ 1.0 10 6 in Iceland), rs700635 is not
the most strongly associated BCC risk variant at the locus.
Although rs700635 is included on the list of potentially causative
variants, it is not extremely well correlated with the index SNP
rs13014235 (r2¼ 0.48) and rs13014235 retains a nominally
signiﬁcant BCC association signal when adjusted for the effect
of rs700635 (Padj¼ 0.022, Supplementary Data 1). The relation-
ship between BCC risk and CASP8 transcript variant expression
therefore remains tentative and merits further study. There are
genes besides CASP8 at the 2q33 locus that should be considered.
Like CASP8, CASP10 encodes an extrinsic apoptosis initiator
caspase. It is less well characterized, in part, because it has no
counterpart in mice. Somatic mutations in CASP10 have been
found in gastric cancer and non-Hodgkin’s lymphoma49,50. Also,
in the region is STRADB, encoding a pseudokinase that
complexes with STK11 and may have anti-apoptotic functions51.
The closest gene to the 10p14 signal is GATA3, encoding a
C2H2 zinc ﬁnger type transcription factor that binds to sequences
resembling A/TGATAA/G in the proximity of target genes, where
it can activate or repress transcription. GATA3 is involved in
lineage speciﬁcation and differentiation in a variety of settings,
including T cells, mammary gland epithelia and skin52. In skin,
GATA3 is involved in lineage determination of the inner root
sheath of the hair follicle. GATA3-knockout mice and conditional
knockouts, where GATA3 is speciﬁcally disrupted in the skin,
show a failure of correct speciﬁcation of inner root sheath cells
and consequent disruption of hair follicle development53,54. In
normal interfollicular skin, GATA3 is expressed in the suprabasal
layer and persists throughout the differentiating layers54,55.
GATA3 knockouts show a hyperplasia of the basal layer,
disruption of the stratiﬁed epithelial differentiation programme
and skin barrier defects53,54,56. Taken together with our
association data these reports suggest that, in humans, variants
at the GATA3 locus may affect the speciﬁcation and
differentiation programme of the epidermis.
Although GATA3 is the nearest gene to the variants we
describe at 10p14, the signal peak is nevertheless a substantial
distance (4800 kb) downstream of the gene. Analysis of
ENCODE data revealed two highly correlated variants
(rs17413266 and rs144203968) that occur in ChIP-Seq veriﬁed
GATA3 binding sites. Ouyang et al.57 have shown that in CD4þ
T cells, GATA3 initiates an auto-activation feedback loop that
promotes ongoing GATA3 expression and stabilizes Th2 lineage
commitment. The molecular details of this auto-activation have
never been worked out and it is not known if a similar feedback
loop occurs in differentiating epidermis.
In summary, we have found four new BCC susceptibility loci.
While the mechanisms at two of the loci remain cryptic, we
provide testable hypotheses for roles of CASP8 and GATA3
variants in epidermal carcinogenesis.
Methods
Subjects. Approval for the Icelandic study was granted by the Icelandic National
Bioethics Committee and the Icelandic Data Protection Authority. All participants
provided informed consent. Affected individuals were identiﬁed through the Ice-
landic Cancer Registry (ICR), which has maintained records of BCC diagnoses
since 1981. The records contained only cases of histologically veriﬁed BCC, sourced
from all the pathology laboratories in the country that deal with these lesions.
Icelandic controls consisted of individuals selected from other ongoing association
studies at deCODE and who did not have a diagnosis of BCC recorded in the ICR.
Median age at diagnosis for ICR notiﬁed cases was 68 years (range 10–104). All
subjects were of European ancestry. Compared with our most recent prior pub-
lication on BCC16, the present study adds 364 new BCC cases and 156,950 new
controls. Of these, 254 cases and 16,944 controls were typed on Illumina chips
resulting in a total of 17,198 new chip genotypes being available to the study. There
was also an increase in the numbers of close relatives for whom genotype
probabilities could be used: 110 additional BCC cases and 140,006 controls.
Eastern European BCC cases were recruited from all general hospitals in three
study areas in Hungary, two in Romania and one in Slovakia. Cases were identiﬁed
based on histopathological examinations by pathologists. The median age at
diagnosis was 67 years (range 30–85). Controls were recruited from the same
hospitals from surgical, orthopaedic and trauma patients. Controls were
thoroughly screened and individuals with past or current BCC, malignant disease,
cardiovascular disease or diabetes were excluded. All subjects were of self-reported
European ancestry. The study was approved by the Ethical Committee of the
National Health Research Council, Hungary. In Romania, ethical aspects of the
study were approved by Environmental Health Centre and Public Health
Department. In Slovakia, ethical aspects of the study were approved by the Ethical
Committee of State Health Institutes.
Spain Valencia. Participants were recruited from the outpatient dermatology
clinics of the Instituto Valenciano de Oncologı´a in Valencia, Spain, starting from
May 2003. Cases were patients with histologically proven BCC presenting with
superﬁcial or nodular lesions ofo1 cm in diameter. Clinical and pathological data
from these patients are prospectively collected by medical history review, personal
interview and clinical examination by an expert dermatologist.
Immunocompromised patients were excluded as were those with any autoimmune
disease, hereditary disorders that include the presence of BCC (Gorlin syndrome,
xeroderma pigmentosum) and epidermodysplasia verruciformis. Controls were
disease free and ethnically matched healthy subjects recruited at the Transfusion
Centre of Valencia. Phenotypic characteristics of controls were obtained by a self-
administered structured questionnaire. Prospective controls reporting past or
present BCC were excluded. All subjects were of self-reported European ancestry.
All patients in the study had signed an informed consent and the study protocol
was approved by the ethics boards of the Instituto Valenciano de Oncologı´a and
the Transfusion Centre of Valencia.
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Spain Zaragoza. BCC cases were recruited from the Oncology Department of
Zaragoza University Hospital starting from September 2007. Individuals with
histologically proven invasive BCC were eligible to participate in the study.
The median time interval from BCC diagnosis to collection of blood samples
was 14 months (range 1–53 months). Median age at diagnosis was 69 years (range
21–91). Controls were recruited from individuals who attended the Zaragoza
University Hospital for diseases other than cancer. Prospective control subjects
were questioned by the recruiter about past or present malignant disease, including
BCC, and those with a positive history were excluded. All subjects were of self-
reported European ancestry. All subjects in the study had signed an informed
consent and the study protocol was approved by the Zaragoza University Hospital
ethics board.
Denmark. Subjects were participating in the ‘Diet, Cancer and Health’ study,
which is a prospective study of 57,053 individuals recruited at two centres in
Denmark between December 1993 and May 1997 (ref. 58). Subjects were
monitored during the follow-up period and BCC cases were identiﬁed through
linkage to entries in the Danish Cancer Registry. Each case identiﬁed was matched
to one control from the Diet, Cancer and Health cohort based on gender, age on
study entry and age at diagnosis of the case. Median age at diagnosis was 59 (range
50–68). In addition to extensive diet and lifestyle questions, subjects answered
questions regarding their skin sensitivity to sun, tanning during summer, presence
of nevi and presence of freckles. All subjects were of self-reported European
ancestry. The study ‘Diet, Cancer and Health’ has been approved by the regional
Ethical Committees on Human Studies in Copenhagen and Aarhus, and by the
Danish Data Protection Agency. Informed consent was obtained from all
participants to search information from medical registers including the Danish
Cancer Register.
Illumina SNP chip genotyping. The Icelandic chip-typed samples were assayed
with the Illumina HumanHap300, HumanHapCNV370, HumanHap610, 1M, or
Omni-Quad bead chips at the deCODE Genetics facility. All samples with a call
rate of o97% were removed from the analysis. SNPs were excluded if they had
(i) a yield lower than 95%, (ii) a minor allele frequency ofo0.01 in the population,
(iii) an excessive deviation from the Hardy–Weinberg equilibrium (Po10 6),
(iv) an excessive inheritance error rate (40.001) or (v) if there was a substantial
difference in allele frequency between chip types (in which case the SNP was
removed from a single chip type if that resolved the difference, but if it did not then
the SNP was removed from all chip types). None of the SNPs listed in Table 1
showed a signiﬁcant association with chip type (P values were between 0.11 and
0.77, tested using logistic regression).
Whole-genome sequencing imputation and association testing. In this study,
we sequenced 2,636 Icelanders to a median depth of 20 . Long-range haplotype
phasing and genealogy-based calculation of genotype probabilities15,19–21 of the
variants identiﬁed by sequencing allowed us to perform 24,988,228 tests of
association; 19,543,184 tests for SNPs and 5,445,044 tests for small indels
(r60 bp). We tested only alleles that could be imputed with an information value
Z0.8, where the informativeness of genotype imputation was estimated by the
ratio of the variance of imputed expected allele counts to the variance of the actual
allele counts, as described previously15. This permitted us to test variants down to a
minor allele frequency of B0.1%. In association testing, we tested each allele
against all other alleles at that position combined. Thus, for biallelic variants, this
corresponds to one test, whereas for multi-allelic variants this corresponds to n
tests, where n is the number of qualifying alleles. All SNP and indel locations are
given in NCBI hg18/Build 36 coordinates unless otherwise speciﬁed. Indels are
designated as chr:position:I. Multi-allelic variants are designated as
chr:position:0:allele, for example, ‘chr8:77605042:0:GAA’.
We imputed the genotypes of 4,572 Icelanders with BCC (cases) and 266,358
controls. The BCC cases were comprised of 2,980 individuals who had been directly
typed on Illumina SNP genotyping microarray chips and 1,592 close relatives of
chip-typed individuals. The controls were comprised of 87,820 chip-genotyped
individuals and 178,538 close relatives of chip-typed individuals. For the
HumanHap series of chips, 304,937 SNPs were used for long-range phasing,
whereas for the Omni series of chips 564,196 SNPs were used. An initial
imputation step was carried out on each chip series separately to create a single
harmonized, long-range phased genotype data set consisting of 707,525 SNPs. In
this ﬁrst step, sharing between individuals with the same long (410 cM)
haplotypes was used to ﬁll in genotypes of SNPs not present on both chip
platforms. So, for example, if a parent was genotyped with a HumanHap series chip
and an offspring with an Omni chip, then the alleles of the transmitted
chromosome can be inferred for both individuals. Since chip genotypes are
available for a large fraction of the Icelandic population (which currently numbers
320,000), this process is quite complete with only 1% of alleles remaining
unknown. Subsequently, this genotype data set was used in the second step of
imputing the full set of variants which was used in the 24,988,228 tests of
association. Association testing was performed using logistic regression, treating
disease status as the response and genotype counts as covariates. Other available
individual characteristics that correlate with disease status were also included in the
model as nuisance variables. These characteristics were gender, county of birth,
current age or age at death (ﬁrst- and second-order terms included), blood sample
availability for the individual and an indicator function for the overlap of the
lifetime of the individual with the timespan of phenotype collection21. Correction
for familial relatedness was carried out using genomic control and P values were
adjusted accordingly (l¼ 1.2374). Tests for heterogeneity were performed by
comparing the null hypothesis of the effect being the same in all populations to the
alternative hypothesis of each population having a different effect, using a
likelihood ratio test. For conditional analyses, the allele count of each individual
was given as a covariate in the logistic regression. All r2 values quoted refer to the
Icelandic population and were determined using long-range haplotype phasing and
imputation.
Assessment for overlap with regulatory regions. To identify a set of BCC-
associated variants that might have regulatory effects, we took the index variant
at each locus and adjusted its association signal in turn for the effect of each
other variant within±500 kb. If the resulting Padj was40.001, we considered that
the tested variant could not safely be distinguished from the index variant and
should therefore be evaluated for potential regulatory and pathogenic effect
(irrespective of its r2 value relative to the index variant). This resulted in sets
containing 45 variants for 2p24 MYCN, 41 variants for 8q21 ZFHX4, 52 variants
for 10p14 GATA3 and 195 variants for the 2q33 CASP8-ALS2CR12 locus. Note
that for this analysis, we used only variants that were detected by the whole-
genome sequencing and which could be imputed with stringent information
values Z0.9 (ref. 15).
For each variant in the sets thus identiﬁed, we searched for overlaps with known
regulatory regions as follows: ﬁrst, we used ENSEMBL to determine whether the
variant had been assigned a regulatory region ENSR number. Then we examined
the ENCODE data and recorded any evidence of ChIP-Seq transcription factor
binding, DNaseI hypersensitivity sites, enhancer and promoter chromatin
segmentation states59–61. We also recorded enhancer and promoter chromatin
segmentation states using the 25 state HMM from the Roadmap consortium62.
Then we looked for correlations between DNaseI hypersensitive sites and local
gene expression using results described by Shefﬁeld et al.63 We examined SiPhy
and GERP conservation scores and the Combined Annotation-Dependent
Depletion Scaled C-score25,64,65. We also viewed the Factorbook and HaploReg_v2
data66,67 (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) to
search for potential changes in transcription factor-binding motifs but we did not
annotate the variants with these data unless there was ChIP-Seq evidence of the
cognate transcription factor binding at that location. To narrow down the variants
for scrutiny at each locus, we pass-ﬁltered the variants on (a) being the index BCC-
associated marker at the locus or (b) presence of an ENSR number or (c) a
reference to normal human keratinocytes (NHEK) or primary foreskin
keratinocytes (PFK) in the annotations derived above. After ﬁltration, there
remained 2 variants at MYCN, 3 at ZFHX4, 2 at GATA3 and 32 at CASP8-
ALS2CR12. We manually checked the data for each of these variants in the UCSC
GRCh37/hg19 Test Genome Browser and by using HaploReg_v2. The results were
tabulated using a style based on the HaploReg_v2 presentation (Supplementary
Data 1). We also manually checked the annotations for the unﬁltered variants with
Padj40.001 from each locus. This resulted in the identiﬁcation of two additional
variants at the GATA3 locus that are located in GATA3 transcription factor-
binding sites but did not meet the pass-ﬁlter qualiﬁcations (see main text and
Supplementary Data 1).
Gene expression microarrays. Samples of RNA from human peripheral blood
(N¼ 1001) and adipose tissue (N¼ 673) were hybridized to Agilent Technologies
Human 25K microarrays26. We quantiﬁed the expression changes between two
samples as the mean logarithm (log10) expression ratio (MLR) compared with a
reference pool RNA sample. In comparing the expression levels between groups of
individuals with different genotypes, we denoted the expression level for each
genotype as 10(average MLR), where the MLR is averaged over individuals with the
particular genotype. We determined the s.e. and signiﬁcance by regressing the MLR
values against the number of risk alleles carried. We took into account the effects of
age, gender and differential cell type count in blood as explanatory variables in the
regression. P values were adjusted for familial relatedness of the individuals by
simulation. No signiﬁcant eQTLs were associated with the risk alleles at the 2p24
MYCN, 8q21 ZFHX4 or 10p14 GATA3 loci.
RNA-seq. For preparation of poly-A complementary DNA (cDNA) sequencing
libraries, the quality and quantity of isolated total RNA from 261 peripheral blood
samples was assessed using the Total RNA 6000 Nano chip for the Agilent 2100
Bioanalyzer. Samples were from different individuals than those who had been
sampled for the gene expression microarray studies described above. cDNA
libraries derived from Poly-A mRNA were generated using Illumina’s TruSeq RNA
Sample Prep Kit. In brief, Poly-A mRNA was isolated from total RNA samples
(1–4 mg input) using hybridization to Poly-T beads. The Poly-A mRNA was
fragmented at 94 C, and ﬁrst-strand cDNA was prepared using random hexamers
and the SuperScript II reverse transcriptase (Invitrogen). Following second-strand
cDNA synthesis, end repair, addition of a single A base, adaptor ligation, AMPure
bead puriﬁcation and PCR ampliﬁcation, the resulting cDNA was measured on a
Bioanalyzer using the DNA 1000 Lab Chip.
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Samples for sequencing were clustered on to ﬂowcells using Illumina’s cBot and
the TruSeq PE cluster kits v2, respectively. Paired-end sequencing (2 76 cycles)
was performed with either GAIIx instruments using the TruSeq SBS kits v5 from
Illumina or HiSeq 2000 instruments using TruSeq v3 ﬂowcells/SBS kits. In some
instances, the read length was 2 50 or 2 101 cycles. Approximately, 125–175
million forward reads (250–350M total reads) were sequenced per sample.
RNA sequencing reads were aligned to Homo sapiens Build 36 with TopHat68
version 1.4.1 with a supplied set of known transcripts in GTF format (RefSeq hg18;
Homo sapiens, NCBI, build36.3). TopHat was conﬁgured such that it attempts ﬁrst
to align reads to the provided transcriptome then, for reads that do not map fully to
the transcriptome, it attempts to map them onto the genome. Read mapping
statistics used for read count normalization were calculated using the
CollectRnaSeqMetrics tool in Picard version 1.79 (http://picard.sourceforge.net/
command-line-overview.shtml#CollectRnaSeqMetrics). Once read alignment by
TopHat was ﬁnished, gene expression estimation was done using Cufﬂinks68
version 1.3.0 for the same set of transcripts used in the read alignment by TopHat.
For analysis of RNA-seq samples, the normalized read count was determined
for each bp location as the number of reads covering the base/the total number of
aligned reads in the individual in billions. Then the median normalized read count
for each genotype group was determined for each bp location and plotted
graphically. To quantify the levels of expression in different regions, the median of
normalized read counts over the genomic segment in question was determined for
each individual. We then did a logarithmic transformation of the normalized read
counts and standardized them so that the response variable had a mean 0 and s.d.
of 1. We determined the effect and signiﬁcance by regressing the transformed read
counts against the number of risk alleles carried. Effect sizes (b) are given in s.d.
units.
Data from the GTEx Release phs000424.v4.p1 from 17.01.2014 were
downloaded from the GTEx consortium35 (http://www.gtexportal.org/home/) via
dbGAP. Analysis was conducted using the provided aligned read and genotype data
as described above for deCODE data. One exception was the integrated CASP8
whole-gene read count by genotype calculation for skin (Supplementary Table 2)
which was taken directly from the GTEx portal and employed their methods (see
URLs).
RT–PCR. We converted total RNA (from a subset of 76 of the blood RNA samples
that were used for the expression microarrays) to cDNA using the High Capacity
cDNA Archive Kit (Applied Biosystems), primed with random hexamers. We
designed assays spanning the exon–intron junction between exons 8 and 9 (RT–
PCR common isoforms, Fig. 2, F-primer: 50-tatatcccggatgaggctga-30 , R-primer: 50-
tcaatcagaagggaagacaagtt-30), spanning from exon 6 to a sequence unique to exon
8L (RT–PCR 8L splice variant, Fig. 2, F-primer: 50-gcctgctgaagataatcaacg-30 ,
R-primer: 50-gaaacatggcccttttggta-30) and contained within intron 8, 50 to the
NM_033358 probe sequence (RT–PCR retained intron, Fig. 2, F-primer: 50-
tcaatttatgaatggacaaccaa-30 , R-primer: 50-cctctctttcgtattagagcctttc-30). Primer
sequences are available on request. We carried out quantitative PCR according to
the manufacturer’s instructions on an ABI Prism 7900HT Sequence Detection
System. We assessed differences in mean relative RNA abundance between geno-
typic groups by regression, as described above for expression microarrays.
References
1. Epstein, E. H. Basal cell carcinomas: attack of the hedgehog. Nat. Rev. Cancer 8,
743–754 (2008).
2. Mohan, S. V. & Chang, A. L. S. Advanced basal cell carcinoma: epidemiology
and therapeutic innovations. Curr. Dermatol. Rep. 3, 40–45 (2014).
3. Scherer, D. & Kumar, R. Genetics of pigmentation in skin cancer—a review.
Mutat. Res. 705, 141–153 (2010).
4. Fan, Z. et al. A missense mutation in PTCH2 underlies dominantly inherited
NBCCS in a Chinese family. J. Med. Genet. 45, 303–308 (2008).
5. Pastorino, L. et al. Identiﬁcation of a SUFU germline mutation in a family with
Gorlin syndrome. Am. J. Med. Genet. A 149A, 1539–1543 (2009).
6. Smyth, I. et al. Isolation and characterization of human patched 2 (PTCH2), a
putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma
on chromosome 1p32. Hum. Mol. Genet. 8, 291–297 (1999).
7. Bastiaens, M. T. et al. Melanocortin-1 receptor gene variants determine the risk
of nonmelanoma skin cancer independently of fair skin and red hair. Am. J.
Hum. Genet. 68, 884–894 (2001).
8. Box, N. F. et al. Melanocortin-1 receptor genotype is a risk factor for basal and
squamous cell carcinoma. J. Invest. Dermatol. 116, 224–229 (2001).
9. Gudbjartsson, D. F. et al. ASIP and TYR pigmentation variants associate with
cutaneous melanoma and basal cell carcinoma. Nat. Genet. 40, 886–891 (2008).
10. Stacey, S. N. et al. New common variants affecting susceptibility to basal cell
carcinoma. Nat. Genet. 41, 909–914 (2009).
11. Nan, H., Kraft, P., Hunter, D. J. & Han, J. Genetic variants in pigmentation
genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int. J.
Cancer 125, 909–917 (2009).
12. Han, J. et al. A germline variant in the interferon regulatory factor 4 gene as a
novel skin cancer risk locus. Cancer Res. 71, 1533–1539 (2011).
13. Praetorius, C. et al. A polymorphism in IRF4 affects human pigmentation
through a tyrosinase-dependent MITF/TFAP2A pathway. Cell 155, 1022–1033
(2013).
14. Stacey, S. N. et al. Common variants on 1p36 and 1q42 are associated with
cutaneous basal cell carcinoma but not with melanoma or pigmentation traits.
Nat. Genet. 40, 1313–1318 (2008).
15. Stacey, S. N. et al. A germline variant in the TP53 polyadenylation signal
confers cancer susceptibility. Nat. Genet. 43, 1098–1103 (2011).
16. Stacey, S. N. et al. Germline sequence variants in TGM3 and RGS22 confer risk
of basal cell carcinoma. Hum. Mol. Genet. 23, 3045–3053 (2014).
17. Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with
many cancer types. Nat. Genet. 41, 221–227 (2009).
18. Sigurdardottir, L. G. et al. Data quality at the Icelandic Cancer Registry:
comparability, validity, timeliness and completeness. Acta Oncol. 51, 880–889
(2012).
19. Kong, A. et al. Detection of sharing by descent, long-range phasing and
haplotype imputation. Nat. Genet. 40, 1068–1075 (2008).
20. Kong, A. et al. Parental origin of sequence variants associated with complex
diseases. Nature 462, 868–874 (2009).
21. Steinthorsdottir, V. et al. Identiﬁcation of low-frequency and rare sequence
variants associated with elevated or reduced risk of type 2 diabetes. Nat. Genet.
46, 294–298 (2014).
22. Choi, E. & Cho, C. Expression of a sperm ﬂagellum component encoded by the
Als2cr12 gene. Gene Expr. Patterns 11, 327–333 (2011).
23. Van Raam, B. J. & Salvesen, G. S. Proliferative versus apoptotic functions of
caspase-8 Hetero or homo: the caspase-8 dimer controls cell fate. Biochim.
Biophys. Acta 1824, 113–122 (2012).
24. Jones, E. A., Sajid, M. I., Shenton, A. & Evans, D. G. Basal cell carcinomas
in gorlin syndrome: a review of 202 patients. J. Skin Cancer 2011, 217378
(2011).
25. Kircher, M. et al. A general framework for estimating the relative pathogenicity
of human genetic variants. Nat. Genet. 46, 310–315 (2014).
26. Emilsson, V. et al. Genetics of gene expression and its effect on disease. Nature
452, 423–428 (2008).
27. Horiuchi, T. et al. Dominant expression of a novel splice variant of caspase-8 in
human peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 272,
877–881 (2000).
28. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V. & Wallach, D. Involvement of
MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF
receptor-induced cell death. Cell 85, 803–815 (1996).
29. Eckhart, L. et al. Alternative splicing of caspase-8 mRNA during differentiation
of human leukocytes. Biochem. Biophys. Res. Commun. 289, 777–781 (2001).
30. Nagy, E. & Maquat, L. E. A rule for termination-codon position within intron-
containing genes: when nonsense affects RNA abundance. Trends Biochem. Sci.
23, 198–199 (1998).
31. Muzio, M. et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease,
is recruited to the CD95 (Fas/APO-1) death—inducing signaling complex. Cell
85, 817–827 (1996).
32. Scafﬁdi, C., Medema, J. P., Krammer, P. H. & Peter, M. E. FLICE is
predominantly expressed as two functionally active isoforms, caspase-8/a and
caspase-8/b. J. Biol. Chem. 272, 26953–26958 (1997).
33. Himeji, D. et al. Characterization of caspase-8L: a novel isoform of caspase-8
that behaves as an inhibitor of the caspase cascade. Blood 99, 4070–4078
(2002).
34. Mohr, A. et al. Caspase-8L expression protects CD34þ hematopoietic
progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene
24, 2421–2429 (2005).
35. GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat. Genet.
45, 580–585 (2013).
36. MacPherson, G. et al. Association of a common variant of the CASP8 gene with
reduced risk of breast cancer. J. Natl Cancer Inst. 96, 1866–1869 (2004).
37. Cox, A. et al. A common coding variant in CASP8 is associated with breast
cancer risk. Nat. Genet. 39, 352–358 (2007).
38. Barrett, J. H. et al. Genome-wide association study identiﬁes three new
melanoma susceptibility loci. Nat. Genet. 43, 1108–1113 (2011).
39. Berndt, S. I. et al. Genome-wide association study identiﬁes multiple risk loci
for chronic lymphocytic leukemia. Nat. Genet. 45, 868–876 (2013).
40. Sun, T. et al. A six-nucleotide insertion-deletion polymorphism in the CASP8
promoter is associated with susceptibility to multiple cancers. Nat. Genet. 39,
605–613 (2007).
41. Haiman, C. A. et al. A promoter polymorphism in the CASP8 gene is not
associated with cancer risk. Nat. Genet. 40, 259–260 (2008).
42. Lin, W.-Y. et al. Identiﬁcation and characterisation of novel associations in the
CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum.
Mol. Genet. 24, 285–298 (2014).
43. Huang, M. & Weiss, W. A. Neuroblastoma and MYCN. Cold Spring Harb.
Perspect. Med. 3, a014415 (2013).
44. Roussel, M. F. & Robinson, G. W. Role of MYC in medulloblastoma. Cold
Spring Harb. Perspect. Med. 3, a014308 (2013).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7825 ARTICLE
NATURE COMMUNICATIONS | 6:6825 | DOI: 10.1038/ncomms7825 | www.nature.com/naturecommunications 9
& 2015 Macmillan Publishers Limited. All rights reserved.
45. Eckhart, L., Lippens, S., Tschachler, E. & Declercq, W. Cell death by
corniﬁcation. Biochim. Biophys. Acta 1833, 3471–3480 (2013).
46. Kovalenko, A. et al. Caspase-8 deﬁciency in epidermal keratinocytes triggers an
inﬂammatory skin disease. J. Exp. Med. 206, 2161–2177 (2009).
47. Lee, P. et al. Dynamic expression of epidermal caspase 8 simulates a wound
healing response. Nature 458, 519–523 (2009).
48. Kaiser r, W. J. et al. RIP3 mediates the embryonic lethality of caspase-8-
deﬁcient mice. Nature 471, 368–372 (2011).
49. Park, W. S. et al. Inactivating mutations of the caspase-10 gene in gastric
cancer. Oncogene 21, 2919–2925 (2002).
50. Shin, M. S. et al. Inactivating mutations of CASP10 gene in non-Hodgkin
lymphomas. Blood 99, 4094–4099 (2002).
51. Sanna, M. G. et al. ILPIP, a novel anti-apoptotic protein that enhances XIAP-
mediated activation of JNK1 and protection against apoptosis. J. Biol. Chem.
277, 30454–30462 (2002).
52. Chou, J., Provot, S. & Werb, Z. GATA3 in development and cancer
differentiation: cells GATA have it! J. Cell. Physiol. 222, 42–49 (2010).
53. Kurek, D., Garinis, G. A., van Doorninck, J. H., van der Wees, J. & Grosveld, F.
G. Transcriptome and phenotypic analysis reveals Gata3-dependent signalling
pathways in murine hair follicles. Development 134, 261–272 (2007).
54. Kaufman, C. K. et al. GATA-3: an unexpected regulator of cell lineage
determination in skin. Genes Dev. 17, 2108–2122 (2003).
55. Ra´cz, E. et al. GATA3 expression is decreased in psoriasis and during epidermal
regeneration; induction by narrow-band UVB and IL-4. PLoS ONE 6, e19806
(2011).
56. De Guzman Strong, C. et al. Lipid defect underlies selective skin barrier
impairment of an epidermal-speciﬁc deletion of Gata-3. J. Cell Biol. 175,
661–670 (2006).
57. Ouyang, W. et al. Stat6-independent GATA-3 autoactivation directs IL-4-
independent Th2 development and commitment. Immunity 12, 27–37 (2000).
58. Tjønneland, A. et al. Study design, exposure variables, and socioeconomic
determinants of participation in Diet, Cancer and Health: a population-based
prospective cohort study of 57,053 men and women in Denmark. Scand. J.
Public Health 35, 432–441 (2007).
59. Dunham, I. et al. An integrated encyclopedia of DNA elements in the human
genome. Nature 489, 57–74 (2012).
60. ENCODE. A user’s guide to the encyclopedia of DNA elements (ENCODE).
PLoS Biol. 9, e1001046 (2011).
61. Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine
human cell types. Nature 473, 43–49 (2011).
62. Chadwick, L. H. The NIH Roadmap Epigenomics Program data resource.
Epigenomics 4, 317–324 (2012).
63. Shefﬁeld, N. C. et al. Patterns of regulatory activity across diverse human cell
types predict tissue identity, transcription factor binding, and long-range
interactions. Genome Res. 23, 777–788 (2013).
64. Davydov, E. V. et al. Identifying a high fraction of the human genome to be
under selective constraint using GERPþþ . PLoS Comput. Biol. 6, e1001025
(2010).
65. Garber, M. et al. Identifying novel constrained elements by exploiting biased
substitution patterns. Bioinformatics 25, i54–i62 (2009).
66. Wang, J. et al. Sequence features and chromatin structure around the genomic
regions bound by 119 human transcription factors. Genome Res. 22, 1798–1812
(2012).
67. Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states,
conservation, and regulatory motif alterations within sets of genetically linked
variants. Nucleic Acids Res. 40, D930–D934 (2011).
68. Trapnell, C. et al. Differential gene and transcript expression analysis of
RNA-seq experiments with TopHat and Cufﬂinks. Nat. Protoc. 7, 562–578
(2012).
Acknowledgements
We thank G.H. Olafsdottir of the Icelandic Cancer Registry for assistance in the ascer-
tainment of affected individuals, Eirikur Steingrimsson for helpful comments on the
manuscript and Hjalti Sigurdsson for help with the graphics. In Valencia, Spain the samples
from the Instituto Valenciano de Oncologı´a were retrieved from the Bionbank of the
Instituto Valenciano de Oncologı´a. In Copenhagen, Denmark the study ‘Diet, Cancer and
Health’ was supported by grants from the Danish Cancer Society and ‘Europe Against
Cancer’: European Prospective Investigation into Cancer and Nutrition (EPIC). We are
grateful to the GTEx Consortium for early stage sharing of RNA-seq and genotypic data.
The following acknowledgement refers to the GTEx data: the Genotype-Tissue Expression
(GTEx) Project was supported by the Common Fund of the Ofﬁce of the Director of the
National Institutes of Health. Additional funds were provided by the NCI, NHGRI, NHLBI,
NIDA, NIMH and NINDS. Donors were enrolled at Biospecimen Source Sites funded by
NCI\SAIC-Frederick, Inc. (SAIC-F) subcontracts to the National Disease Research Inter-
change (10XS170), Roswell Park Cancer Institute (10XS171) and Science Care Inc.
(X10S172). The Laboratory, Data Analysis and Coordinating Center (LDACC) was funded
through a contract (HHSN268201000029C) to The Broad Institute Inc. Biorepository
operations were funded through an SAIC-F subcontract to Van Andel Institute
(10ST1035). Additional data repository and project management were provided by SAIC-F
(HHSN261200800001E). The Brain Bank was supported by a supplements to University of
Miami grants DA006227 & DA033684 and to contract N01MH000028. Statistical Methods
development grants were made to the University of Geneva (MH090941 & MH101814),
the University of Chicago (MH090951, MH090937, MH101820, MH101825), the Uni-
versity of North Carolina—Chapel Hill (MH090936 & MH101819), Harvard University
(MH090948), Stanford University (MH101782), Washington University St Louis
(MH101810) and the University of Pennsylvania (MH101822).
Author contributions
S.N.S., H.H., S.A.G., G.T., F.Z., P.S., A.K., D.F.G., U.T., J.H.O. and K.S. designed the study
and interpreted the results. S.N.S., B.S., K.R.B., K.T., R.R., V.F., C.C., Y.G., M.G., D.P.,
O.S., P.R., E.G., K.K., B.A.N., A.T., K.O., J.G.J., L.T., T.R., U.V., R.K., E.N., J.I.M. and
J.H.O carried out the subject ascertainment and recruitment. S.N.S., H.H., G.T., F.Z.,
A.S., H.J., A.M.K., H.S., G.M., O.T.M., T.R. and U.T. performed the sequencing, geno-
typing and expression analyses. S.N.S., H.H., S.A.G., G.T., F.Z., A.S., B.K., P.S., G.M.,
B.V.H., A.K. and D.F.G. performed the statistical and bioinformatics analyses. S.N.S.,
H.H., S.A.G., G.T., F.Z. and K.S. drafted the manuscript. All authors contributed to the
ﬁnal version of the paper. Principle collaborators for the case–control population samples
were B.S. and J.H.O. (Iceland), U.V. (Denmark), R.K. (Eastern Europe), E.N. (Valencia,
Spain) and J.I.M (Zaragoza, Spain).
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: All deCODE authors are employees of the biotechnology
ﬁrm deCODE Genetics, a subsidiary of AMGEN.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Stacey, S. N. et al. New basal cell carcinoma susceptibility loci.
Nat. Commun. 6:6825 doi: 10.1038/ncomms7825 (2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7825
10 NATURE COMMUNICATIONS | 6:6825 | DOI: 10.1038/ncomms7825 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
